Science & CHR-P | NWPharmaTech

What CHR-P means

Clinical high-risk / ultra-high-risk constructs identify people with elevated risk of transitioning to psychosis relative to the general population — often with attenuated psychotic symptoms.

Important: A risk designation is not a diagnosis of schizophrenia and does not mean any individual will inevitably develop psychosis. Transition rates vary by enrichment, era, and care setting.

The unmet need

There is still no broadly approved pharmacotherapy whose labelled claim is to prevent psychosis in clinical high-risk populations across major markets. Early intervention remains an open scientific and clinical frontier.

For many young people and families, the practical questions are urgent: how to reduce distress from attenuated symptoms, support functioning, and — where possible — lower the chance that frank psychosis becomes established. Those goals are related but not identical, and a credible research programme must say which question it is answering at each stage.

Why this programme exists

Conventional capital has often found CHR-P programmes hard to finance: timelines are long, conversion rates vary, and “prevention” is easy to overclaim. NWPharmaTech’s response is to keep sponsor-grade clinical governance while exploring catalytic funding structures that can support a defined scientific step — without letting fundraising language rewrite the evidence.

Our working scientific focus for a first catalytic package is to prepare and run a rigorous evaluation of whether NWPT-SM32300 can help people who meet defined CHR-P criteria on symptom and functioning outcomes that are measurable in a realistic trial window. Larger transition-to-psychosis (prevention/delay) objectives remain important research questions — but they must be separately powered and financed if they are to be claimed as the primary goal.

What this programme is investigating

NWPharmaTech’s investigational candidate for this workstream is described in company materials as NWPT-SM32300, a 300 mg CBD micellar-emulsion softgel (earlier documents may use the name NW300EMCBD — naming is being reconciled).

Proposed programme aim: evaluate whether this formulation can help people meeting defined CHR-P criteria — with endpoints and design still to be locked in a version-controlled protocol synopsis. This is not an established efficacy claim.

What evidence exists vs what we aim to establish

Question	Status today	What would establish it
Is CHR-P a meaningful clinical construct?	Supported by field research (risk is elevated and heterogeneous)	Continued careful use of validated criteria; not a diagnosis of schizophrenia
Is there an approved medicine labelled to prevent psychosis in CHR-P?	No across major markets (field context)	Regulatory-labelled claims after adequate evidence — not marketing language
Does NWPT-SM32300 reach expected exposure vs a reference CBD product?	Management has described early comparative bioavailability work; signed clinical study report required before we publish numbers	Signed CSR/tables for the formulation actually used
Does NWPT-SM32300 improve attenuated symptoms / functioning in CHR-P?	Not established — investigational; protocol synopsis in development	Pre-specified PoC trial with locked endpoints and honest analysis
Does it prevent or delay transition to psychosis?	Not established — mission-level question; not the default first catalytic claim	Adequately powered, long-follow-up trial if pursued as a primary objective

Evidence discipline

Findings from other CBD products or academic CBD studies are not the same as evidence generated with NWPT’s formulation.
Any early clinical bioavailability work, if completed, would speak to exposure/comparability — it would not by itself establish efficacy in CHR-P, prevention of psychosis, chronic safety, or superiority over other treatments.
Historical planning figures (for example large multi-site designs with multiple dose levels) are planning precedents, not a locked protocol, until a version-controlled synopsis exists.
We will not publish numerical PK or safety claims from unsigned summaries.

Statements about the wider CHR-P literature are not claims that NWPharmaTech has proven prevention efficacy, locked a clinical win, or validated confirmatory biomarkers for its programme.

NWPT’s role as sponsor

Established policy: NWPharmaTech remains pharmaceutical sponsor for clinical development, safety, CMC, and regulatory strategy related to this programme. Investigators, ethics committees, and regulators retain their independent roles.

This site does not claim that NWPT-SM32300 prevents psychosis or that a pivotal prevention trial is complete.

Science roadmap

Horizon	Science intent	Status
Now	Informational science pages with clear labelling of proposed vs established	Live / building
Near	Version-controlled clinical synopsis; reconcile product naming; obtain signed early-study reports before any numerical PK/safety claims	In development
Near	Private diligence package: preferred catalytic use-of-proceeds scenario focused on symptom / attenuated-psychosis proof-of-concept preparation (preferred over underpowered “prevention” claims at the working ~$10 million planning target)	In development
Later	Larger transition-to-psychosis objectives only if separately powered and financed	Illustrative / later

Approximately $10 million is a working fundraising target for planning — not a validated trial budget or priced offer. See the FAQ.